Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (169) 169
index medicus (129) 129
male (125) 125
female (122) 122
middle aged (122) 122
adult (105) 105
aged (105) 105
life sciences (88) 88
cancer (85) 85
hematology (85) 85
oncology (82) 82
lymphomas (58) 58
rituximab (56) 56
antineoplastic combined chemotherapy protocols - therapeutic use (53) 53
treatment outcome (52) 52
aged, 80 and over (51) 51
chemotherapy (51) 51
lymphoma (50) 50
non-hodgkins-lymphoma (49) 49
prognosis (48) 48
[ sdv.can ] life sciences [q-bio]/cancer (39) 39
[sdv.can]life sciences [q-bio]/cancer (33) 33
survival (32) 32
b-cell lymphoma (31) 31
elderly-patients (31) 31
lymphoma, large b-cell, diffuse - drug therapy (31) 31
adolescent (29) 29
abridged index medicus (28) 28
disease-free survival (28) 28
hemic and lymphatic diseases (27) 27
young adult (26) 26
retrospective studies (25) 25
therapy (24) 24
care and treatment (22) 22
cyclophosphamide (22) 22
cyclophosphamide - administration & dosage (22) 22
risk factors (22) 22
survival analysis (22) 22
antineoplastic combined chemotherapy protocols - adverse effects (21) 21
expression (21) 21
follow-up studies (21) 21
doxorubicin - administration & dosage (20) 20
kaplan-meier estimate (20) 20
prospective studies (19) 19
antineoplastic agents - therapeutic use (18) 18
cyclophosphamide - therapeutic use (18) 18
neoplasm staging (18) 18
vincristine - administration & dosage (18) 18
antineoplastic combined chemotherapy protocols - administration & dosage (17) 17
doxorubicin (17) 17
lymphoma, large b-cell, diffuse - mortality (17) 17
trial (17) 17
clinical trials (16) 16
doxorubicin - therapeutic use (16) 16
fluorodeoxyglucose f18 (16) 16
immune system diseases (16) 16
lymphoma, large b-cell, diffuse - pathology (16) 16
pathology (16) 16
prednisone - administration & dosage (16) 16
prednisone - therapeutic use (16) 16
antibodies, monoclonal, murine-derived - administration & dosage (15) 15
antibodies, monoclonal, murine-derived - therapeutic use (15) 15
lymphoma, follicular - drug therapy (15) 15
antibodies, monoclonal, murine-derived (14) 14
diagnosis (14) 14
follicular lymphoma (14) 14
lymphoma, large b-cell, diffuse - diagnosis (14) 14
malignant-lymphoma (14) 14
patients (14) 14
vincristine (14) 14
[ sdv ] life sciences [q-bio] (13) 13
[sdv]life sciences [q-bio] (13) 13
analysis (13) 13
drug administration schedule (13) 13
medical research (13) 13
pet (13) 13
positron-emission tomography - methods (13) 13
positron-emission-tomography (13) 13
prednisone (13) 13
risk (13) 13
survival rate (13) 13
time factors (13) 13
follow-up (12) 12
france (12) 12
multivariate analysis (12) 12
mutation (12) 12
radiology, nuclear medicine & medical imaging (12) 12
recurrence (12) 12
transplantation (12) 12
vincristine - therapeutic use (12) 12
aggressive lymphoma (11) 11
antibodies, monoclonal - administration & dosage (11) 11
antineoplastic agents - administration & dosage (11) 11
diffuse large b-cell lymphoma (11) 11
disease (11) 11
gastroenterology & hepatology (11) 11
human health and pathology (11) 11
immunochemotherapy (11) 11
immunohistochemistry (11) 11
leukemia (11) 11
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Clinical features and prognostic factors of listeriosis: the MONALISA national prospective cohort study
by Charlier, Caroline, Dr and Perrodeau, Élodie, MSc and Leclercq, Alexandre, MSc and Cazenave, Benoît, MD and Pilmis, Benoît, MD and Henry, Benoît, MD and Lopes, Amanda, MD and Maury, Mylène M, PhD and Moura, Alexandra, PhD and Goffinet, François, MD and Dieye, Hélène Bracq and Thouvenot, Pierre and Ungeheuer, Marie-Noëlle, MD and Tourdjman, Mathieu, MD and Goulet, Véronique, MD and de Valk, Henriette, MD and Lortholary, Olivier, Prof and Ravaud, Philippe, Prof and Lecuit, Marc, Prof and MONALISA Study Grp and MONALISA study group
Lancet Infectious Diseases, The, ISSN 1473-3099, 2017, Volume 17, Issue 5, pp. 510 - 519
Summary Background Listeriosis is a severe foodborne infection and a notifiable disease in France. We did a nationwide prospective study to characterise its... 
Infectious Disease | MORTALITY | MENINGITIS | INFECTIOUS DISEASES | MONOCYTOGENES | RISK-FACTORS | MANAGEMENT | GUIDELINES | SURVEILLANCE | PREGNANCY | Foodborne Diseases - microbiology | Infant, Newborn, Diseases - epidemiology | Prognosis | Prospective Studies | Humans | Listeriosis - diagnosis | Bacteremia - mortality | Male | Infant, Newborn, Diseases - microbiology | Listeriosis - epidemiology | Mandatory Reporting | Listeria monocytogenes - classification | Adult | Female | Pregnancy Complications, Infectious - microbiology | Infant, Newborn | Meningoencephalitis - epidemiology | France - epidemiology | Meningoencephalitis - mortality | Pregnancy Complications, Infectious - epidemiology | Risk Factors | Listeria monocytogenes - isolation & purification | Hospitalization | Infectious Disease Transmission, Vertical | Pregnancy | Meningoencephalitis - microbiology | Bacteremia - epidemiology | Listeriosis - microbiology | Aged | Population Surveillance | Listeriosis | Neonates | Food-borne diseases | Disease | Brain stem | Clinical trials | Infections | Genomes | Gestation | Epidemiology | Risk factors | Windows (intervals) | Listeria | Meningitis | Public health | Food | Dexamethasone | Bacterial infections | Mortality | Fetuses | Regression analysis | Clustering | Patients | Bacteremia | Meningoencephalitis | Studies | Surveillance | Medical prognosis | Health risk assessment | Cancer | Life Sciences
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial
by Salles, Gilles, Prof and Seymour, John Francis, Prof and Offner, Fritz, Prof and López-Guillermo, Armando, MD and Belada, David, MD and Xerri, Luc, Prof and Feugier, Pierre, Prof and Bouabdallah, Réda, MD and Catalano, John Vincent, FRACP and Brice, Pauline, MD and Caballero, Dolores, MD and Haioun, Corinne, Prof and Pedersen, Lars Moller, MD and Delmer, Alain, Prof and Simpson, David, FRACP and Leppa, Sirpa, MD and Soubeyran, Pierre, Prof and Hagenbeek, Anton, Prof and Casasnovas, Olivier, MD and Intragumtornchai, Tanin, Prof and Fermé, Christophe, MD and da Silva, Maria Gomes, MD and Sebban, Catherine, MD and Lister, Andrew, Prof and Estell, Jane A, FRACP and Milone, Gustavo, MD and Sonet, Anne, MD and Mendila, Myriam, MD and Coiffier, Bertrand, Prof and Tilly, Hervé, Prof
Lancet, The, ISSN 0140-6736, 2011, Volume 377, Issue 9759, pp. 42 - 51
Summary Background Patients with follicular lymphoma can have long survival times, but disease progression typically occurs 3–5 years after initial treatment.... 
Internal Medicine | SINGLE-AGENT | MEDICINE, GENERAL & INTERNAL | PREDNISONE | THERAPY | FREE SURVIVAL | CYCLOPHOSPHAMIDE | VINCRISTINE | NON-HODGKINS-LYMPHOMA | TERM-FOLLOW-UP | INDOLENT | CELL | Lymphoma, Follicular - drug therapy | Humans | Middle Aged | Rituximab | Male | Antineoplastic Agents - therapeutic use | Tumor Burden | Remission Induction | Disease Progression | Young Adult | Aged, 80 and over | Adult | Female | Aged | Antibodies, Monoclonal, Murine-Derived - therapeutic use | Immunologic Factors - therapeutic use | Chemotherapy | Lymphomas | Drug therapy | Health aspects | Cancer | Studies | Stock options | Educational materials | Cancer therapies | Cervical cancer | Tropical diseases | Skin cancer | Side effects | infection | lymphoma | survival | clinical trials | Maintenance | intervention | chemotherapy
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network
by Hermine, Olivier, Prof and Hoster, Eva, PhD and Walewski, Jan, MD and Bosly, André, MD and Stilgenbauer, Stephan, MD and Thieblemont, Catherine, MD and Szymczyk, Michal, MD and Bouabdallah, Reda, MD and Kneba, Michael, Prof and Hallek, Michael, Prof and Salles, Gilles, Prof and Feugier, Pierre, MD and Ribrag, Vincent, MD and Birkmann, Josef, MD and Forstpointner, Roswitha, MD and Haioun, Corinne, MD and Hänel, Mathias, MD and Casasnovas, René Olivier, MD and Finke, Jürgen, MD and Peter, Norma, MD and Bouabdallah, Kamal, MD and Sebban, Catherine, MD and Fischer, Thomas, Prof and Dührsen, Ulrich, Prof and Metzner, Bernd, MD and Maschmeyer, Georg, MD and Kanz, Lothar, Prof and Schmidt, Christian, MD and Delarue, Richard, MD and Brousse, Nicole, MD and Klapper, Wolfram, MD and Macintyre, Elizabeth, Prof and Delfau-Larue, Marie-Hélène, Prof and Pott, Christiane, MD and Hiddemann, Wolfgang, Prof and Unterhalt, Michael, PhD and Dreyling, Martin, Prof and European Mantle Cell Lymphoma and European Mantle Cell Lymphoma Network
Lancet, The, ISSN 0140-6736, 2016, Volume 388, Issue 10044, pp. 565 - 575
Summary Background Mantle cell lymphoma is characterised by a poor long-term prognosis. The European Mantle Cell Lymphoma Network aimed to investigate whether... 
Internal Medicine | 1ST-LINE TREATMENT | MEDICINE, GENERAL & INTERNAL | MULTICENTER | THERAPY | RESPONSE CRITERIA | FREE SURVIVAL | TEMSIROLIMUS | PLUS RITUXIMAB | FOLLOW-UP | CHOP | INDOLENT | Doxorubicin - therapeutic use | Humans | Middle Aged | Lymphoma, Mantle-Cell - drug therapy | Male | Combined Modality Therapy | Cytarabine - adverse effects | Cyclophosphamide - therapeutic use | Cytarabine - administration & dosage | Lymphoma, Mantle-Cell - therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Immunotherapy | Treatment Failure | Vincristine - therapeutic use | Adult | Female | Immunosuppressive Agents - adverse effects | Hematopoietic Stem Cell Transplantation - methods | Transplantation Conditioning | Immunosuppressive Agents - administration & dosage | Prednisone - therapeutic use | Transplantation | Epidemiology | Stem cells | Tumors | Medical informatics | Clinical trials | Chemotherapy | Lymphomas | Clinical outcomes | Life Sciences | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial
by Récher, Christian, Prof and Coiffier, Bertrand, Prof and Haioun, Corinne, Prof and Molina, Thierry Jo, Prof and Fermé, Christophe, MD and Casasnovas, Olivier, MD and Thiéblemont, Catherine, Prof and Bosly, André, Prof and Laurent, Guy, Prof and Morschhauser, Franck, MD and Ghesquières, Hervé, MD and Jardin, Fabrice, Prof and Bologna, Serge, MD and Fruchart, Christophe, MD and Corront, Bernadette, MD and Gabarre, Jean, MD and Bonnet, Christophe, MD and Janvier, Maud, MD and Canioni, Danielle, Prof and Jais, Jean-Philippe, MD and Salles, Gilles, Prof and Tilly, Hervé, Dr, Prof and Grp Etud Lymphomes Adulte and Groupe d'Etude des Lymphomes de l'Adulte
Lancet, The, ISSN 0140-6736, 2011, Volume 378, Issue 9806, pp. 1858 - 1867
Summary Background The outcome of diffuse large B-cell lymphoma has been substantially improved by the addition of the anti-CD20 monoclonal antibody rituximab... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | MULTICENTER | RESPONSE CRITERIA | AGGRESSIVE LYMPHOMAS | POOR-PROGNOSIS | NON-HODGKINS-LYMPHOMA | REGIMEN | YOUNG-PATIENTS | ELDERLY-PATIENTS | DES-LYMPHOMES | TRANSPLANTATION | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prospective Studies | Follow-Up Studies | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Cyclophosphamide - adverse effects | Dose-Response Relationship, Drug | Young Adult | Vindesine - adverse effects | Adult | Female | Prednisolone | Doxorubicin - administration & dosage | Severity of Illness Index | Prednisone - administration & dosage | Lymphoma, Large B-Cell, Diffuse - drug therapy | Prednisone - adverse effects | Drug Administration Schedule | Risk Assessment | Rituximab | Treatment Outcome | Bleomycin - administration & dosage | Bleomycin - adverse effects | Vincristine | Lymphoma, Large B-Cell, Diffuse - mortality | Disease-Free Survival | Lymphoma, Large B-Cell, Diffuse - diagnosis | Maximum Tolerated Dose | Adolescent | Survival Analysis | Vindesine - administration & dosage | Doxorubicin - adverse effects | Chemotherapy | Physiological aspects | Lymphomas | B cells | Drug therapy | Methods | Cancer | Dehydrogenases | Toxicity | Population studies | Doxorubicin | Hepatitis | Randomization | Bleomycin | Motivation | Drug dosages | Neutropenia | Cell survival | Hematology | Prednisone | Survival | Patients | Lymphoma | Cyclophosphamide | Lymphocytes B | Monoclonal antibodies | CD20 antigen | Tumors | B-cell lymphoma | Clinical trials | Public speaking | Grants | Clinical medicine | Side effects | lymphoma | survival | International standardization | chemotherapy
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial
by Peyrade, Frédéric, Dr and Jardin, Fabrice, Prof and Thieblemont, Catherine, Prof and Thyss, Antoine, Prof and Emile, Jean-François, Prof and Castaigne, Sylvie, Prof and Coiffier, Bertrand, Prof and Haioun, Corinne, Prof and Bologna, Serge, MD and Fitoussi, Olivier, MD and Lepeu, Gérard, MD and Fruchart, Christophe, MD and Bordessoule, Dominique, MD and Blanc, Michel, MD and Delarue, Richard, Prof and Janvier, Maud, MD and Salles, Bruno, MD and André, Marc, MD and Fournier, Marion and Gaulard, Philippe, Prof and Tilly, Hervé, Prof and Grp Etud Lymphomes Adulte Investig and Groupe d'Etude des Lymphomes de l'Adulte (GELA) investigators
Lancet Oncology, The, ISSN 1470-2045, 2011, Volume 12, Issue 5, pp. 460 - 468
Summary Background Diffuse large B-cell lymphoma is a common cancer in elderly patients. Although treatment has been standardised in younger patients, no... 
Hematology, Oncology and Palliative Medicine | MAINTENANCE RITUXIMAB | COLONY-STIMULATING FACTOR | PROGNOSTIC-FACTORS | RESPONSE CRITERIA | ONCOLOGY | AGGRESSIVE LYMPHOMAS | MALIGNANT-LYMPHOMAS | NON-HODGKINS-LYMPHOMA | COMPREHENSIVE GERIATRIC ASSESSMENT | DETUDE-DES-LYMPHOMES | CHOP CHEMOTHERAPY | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prognosis | Prospective Studies | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Cyclophosphamide - adverse effects | Aged, 80 and over | Vincristine - administration & dosage | Female | France | Odds Ratio | Doxorubicin - administration & dosage | Prednisone - administration & dosage | Lymphoma, Large B-Cell, Diffuse - drug therapy | Prednisone - adverse effects | Drug Administration Schedule | Lymphoma, Large B-Cell, Diffuse - pathology | Risk Assessment | Risk Factors | Rituximab | Treatment Outcome | Lymphoma, Large B-Cell, Diffuse - mortality | Disease-Free Survival | Analysis of Variance | Belgium | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Vincristine - adverse effects | Doxorubicin - adverse effects | Antibodies, Monoclonal, Murine-Derived - therapeutic use | Anthracyclines | Cyclophosphamide | Chemotherapy | Corticosteroids | Oncology, Experimental | Aged patients | Product development | Prednisone | Lymphomas | Research | Cancer | Toxicity | Albumin | Clinical trials | Multivariate analysis | Doxorubicin | Survival | Vincristine | Side effects | Motivation | Age | rituximab | B-cell lymphoma | Geriatrics | Neutropenia
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights